News

Basel, Switzerland. May 5th, 2020. 09:00 CEST The Global Antibiotic Research and Development Partnership (GARDP) has today announced an agreement with Swiss biopharmaceutical company BioVersys to explore opportunities to accelerate the research and development of antibiotics for serious bacterial infections. The Memorandum of Understanding includes supporting BioVersys in the preparation of a paediatric investigational plan […]

FOR DEVELOPMENT OF FIRST-IN-CLASS STAND-ALONE ANTI-VIRULENCE SMALL MOLECULE DRUGS – A PARADIGM SHIFT IN AMR THERAPY Basel, Switzerland, October 29, 2019. 09:00 CET CARB-X funds BioVersys up to US$ 8.92 million to support the development of first-in-class anti-virulence small molecule drugs that disarm bacteria, opening the door for a paradigm shift in AMR therapy. BioVersys

Basel, Switzerland, June 20, 2019. 13:00 CET BioVersys has been awarded EUR 6.92 Million funding for TRIC-TB from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853800. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. BioVersys is pleased to announce that it has

Basel, Switzerland, May 27, 2019. 09:00 CET BioVersys Receives QIDP Designation from the U.S. FDA for the Development of BV100 BioVersys AG a privately owned, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, announced today that its

Basel, Switzerland, December 05, 2018. 09:00 CET Dr. Glenn E. Dale Appointed Chief Development Officer of BioVersys BioVersys is strengthening its executive management team with the appointment of Dr. Glenn E. Dale as Chief Development Officer as of February 1st, 2019. He will lead clinical development activities and brings 25 years of R&D experience and

Basel, Switzerland, November 15, 2018. 09:00 CET BioSystems Technology, BioVersys and Voxcan join forces to establish IMPACT2 – an Innovative Multifaceted Platform for Antimicrobial Commercialisation Transformation Powered by Eurostars – a joint programme co-funded by EUREKA member countries and the European Union Horizon 2020 Framework Programme BioSystems Technology, BioVersys and Voxcan announce funding for a

Basel, Switzerland, November 15, 2018. 09:00 CET BioSystems Technology, BioVersys and Voxcan join forces to establish IMPACT2 – an Innovative Multifaceted Platform for Antimicrobial Commercialisation Transformation Powered by Eurostars – a joint programme co-funded by EUREKA member countries and the European Union Horizon 2020 Framework Programme BioSystems Technology, BioVersys and Voxcan announce funding for a

BioVersys s’implante à Lille pour intensifier la recherche et le développement de nouveaux antibiotiques afin de combattre la résistance bactérienne, en collaboration avec des équipes de recherche lilloises En collaboration avec l’Institut Pasteur de Lille, l’Inserm, le CNRS, l’Université de Lille et la SATT Nord, BioVersys, société biopharmaceutique suisse, va renforcer la recherche et le

Basel, November 20, 2017 BioVersys AG announced today that it has successfully closed a Series A2 financing round of CHF 5 million with existing private investors. “We would like to thank our investors for their ongoing support. The funds will be used to prepare for clinical development with BioVersys’ lead project directed at Tuberculosis and